European Investor
13 Nov 2025, 12:25
Merck reports solid Q3 growth driven by Process Solutions, Rare Diseases and semiconductor demand
Merck delivered solid organic growth in the third quarter of 2025, supported by strong performances in Process Solutions, Rare Diseases and Semiconductor Solutions despite significant currency headwinds. Net sales rose organically by 5.2% to 5.3 billion euros, while EBITDA pre grew organically by 8.8% to 1.7 billion euros. Reported growth was held back by negative foreign exchange effects, but margins improved thanks to one-time gains and strong operational execution.
Life Science’s Process Solutions unit continued to lead sector growth with double-digit organic expansion, reflecting ongoing high demand in biopharmaceutical production. Healthcare benefited from strong results in cardiovascular, metabolism and endocrinology treatments, as well as continued momentum in Mavenclad and Erbitux. The newly added Rare Diseases franchise, supported by the SpringWorks acquisition, boosted portfolio contributions.
Electronics saw steady growth, driven mainly by Semiconductor Materials, where AI-related demand for advanced chip technologies remained strong.
Merck confirmed its full-year 2025 guidance, expecting up to 21.4 billion euros in net sales and continued EBITDA pre growth, supported by its diversified portfolio and strategic investments, including expanded access to fertility treatments in the United States.
Merck delivered solid organic growth in the third quarter of 2025, supported by strong performances in Process Solutions, Rare Diseases and Semiconductor Solutions despite significant currency headwinds. Net sales rose organically by 5.2% to 5.3 billion euros, while EBITDA pre grew organically by 8.8% to 1.7 billion euros. Reported growth was held back by negative foreign exchange effects, but margins improved thanks to one-time gains and strong operational execution.
Life Science’s Process Solutions unit continued to lead sector growth with double-digit organic expansion, reflecting ongoing high demand in biopharmaceutical production. Healthcare benefited from strong results in cardiovascular, metabolism and endocrinology treatments, as well as continued momentum in Mavenclad and Erbitux. The newly added Rare Diseases franchise, supported by the SpringWorks acquisition, boosted portfolio contributions.
Electronics saw steady growth, driven mainly by Semiconductor Materials, where AI-related demand for advanced chip technologies remained strong.
Merck confirmed its full-year 2025 guidance, expecting up to 21.4 billion euros in net sales and continued EBITDA pre growth, supported by its diversified portfolio and strategic investments, including expanded access to fertility treatments in the United States.